Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Colgate Q3 earnings

This article was originally published in The Tan Sheet

Executive Summary

Increased media and commercial efforts will continue next year, but the firm intends to prioritize spending, resulting in a smaller bump compared with this fiscal year, CEO Reuben Mark says during an Oct. 20 third-quarter earnings call. Colgate recently revised its forecast to reflect lower-than-expected earnings as a result of the increased spending (1"The Tan Sheet" Sept. 27, 2004, p. 7). Worldwide sales grew 6.8% to $2.7 bil., but net income fell nearly 10% to $329 mil. North American sales in the oral, personal and home care divisions increased 3.8% to $623.3 mil., and operating profit advanced 4.7% to $137.2 mil. The firm also announced it will buy back 20 mil. shares of stock by the end of 2005...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS097428

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel